---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-044416"
form_type: "8-K"
ticker: "INGN"
cik: "0001294133"
company_name: "Inogen Inc"
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:49:56.380097+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inogen EVP R&D & Chief Medical Officer Stanislav Glezer to depart by May 3, 2024

## Summary
- Mutual separation of Dr. Stanislav Glezer, EVP R&D and Chief Medical Officer, effective on or before May 3, 2024.
- Company expects to enter a separation agreement with benefits consistent with his existing 2021 severance agreement.
- No successor named; disclosure of separation agreement terms to be filed later.
- Glezer was responsible for R&D and clinical strategy; departure leaves a key leadership gap.

## SEC filing metadata
- accession: 0000950170-24-044416
- form_type: 8-K
- ticker: INGN
- cik: 0001294133
- company_name: Inogen Inc
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/0000950170-24-044416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/ingn-20240411.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-044416
- JSON: https://secwatch.observer/filing/0000950170-24-044416.json
- Plain text: https://secwatch.observer/filing/0000950170-24-044416.txt

## Key facts
- Executive change
  Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.
  - Action: separated
  - Role: Executive Vice President, R&D and Chief Medical Officer
  source text: On April 11, 2024, Inogen, Inc. (the “Company”) and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/0000950170-24-044416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.